PDS Biotechnology Corporation

114 articles with PDS Biotechnology Corporation

• PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results

  11/10/2021

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended September 30, 2021 and provide a business update on its conference call.

• PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

  11/8/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), today announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP).

• PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

  11/1/2021

  PDS Biotechnology Corporation today announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate.

• PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

  10/27/2021

  PDS Biotechnology Corporation today announced that the company’s Chief Medical Officer, Dr. Lauren V. Wood, will be presenting at the upcoming 2021 International Head and Neck Cancer Conference

• 

  Clinical Catch-Up: October 18-22

  10/25/2021

  It was yet another busy week for clinical trial news. Here’s a look.

• PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationTemporary administrative suspension of recruitment

  10/21/2021

  PDS Biotechnology Corporation today announced the temporary suspension of recruitment in the National Cancer Institute (NCI)-led Phase 2 clinical trial (NCT04287868) evaluating PDS0101 (Versamune ® -HPV16) in combination with two investigational immune-modulating agents in advanced HPV cancers.

• PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

  10/13/2021

  PDS Biotechnology Corporation will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

  10/6/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Matthew Hill will join PDS Biotech as its Chief Financial Officer (CFO) effective as of October 18, 2021.

• PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer

  10/4/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), today announced the completion of enrollment for the first stage of the checkpoint inhibitor naïve arm of its VERSATILE-002 Phase 2 study for the treatment of recurrent and/or metastatic human papillomavirus (HPV16)-associated head and neck cancer.

• PDS Biotechnology to Present at the Benzinga Healthcare Conference

  9/27/2021

  PDS Biotechnology Corporation today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.

• PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

  9/22/2021

  PDS Biotechnology Corporation today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. 

• PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

  9/20/2021

  PDS Biotechnology Corporation today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV16)-associated head and neck cancer achieved its preliminary safety benchmark in its first 12 patients.

• PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 15, 2021

  9/15/2021

  PDS Biotechnology Corporation announced that the compensation committee of the board of directors of the Company approved, on September 13, 2021, an equity award to Gregory Reid, the Company’s new VP of Program Development, as a material inducement to Mr. Reid entering into employment with PDS Biotech.

• PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 

  9/13/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

  9/9/2021

  PDS Biotechnology Corporation today announced that it has completed the enrollment of the lead-in safety cohort of its VERSATILE-002 Phase 2 study evaluating the efficacy and safety of the combination of PDS0101

• PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.  The presentation will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on

• PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

  8/12/2021

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call

• PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

  7/28/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021. 

• PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

  7/26/2021

  PDS Biotechnology Corporation will release financial results for the second quarter of 2021 on Thursday, August 12, 2021, before the market opens.